Longitudinal Metabolome-Wide Signals Prior to the Appearance of a First Islet Autoantibody in Children Participating in the TEDDY Study
- PMID: 32029481
- PMCID: PMC7034190
- DOI: 10.2337/db19-0756
Longitudinal Metabolome-Wide Signals Prior to the Appearance of a First Islet Autoantibody in Children Participating in the TEDDY Study
Abstract
Children at increased genetic risk for type 1 diabetes (T1D) after environmental exposures may develop pancreatic islet autoantibodies (IA) at a very young age. Metabolic profile changes over time may imply responses to exposures and signal development of the first IA. Our present research in The Environmental Determinants of Diabetes in the Young (TEDDY) study aimed to identify metabolome-wide signals preceding the first IA against GAD (GADA-first) or against insulin (IAA-first). We profiled metabolomes by mass spectrometry from children's plasma at 3-month intervals after birth until appearance of the first IA. A trajectory analysis discovered each first IA preceded by reduced amino acid proline and branched-chain amino acids (BCAAs), respectively. With independent time point analysis following birth, we discovered dehydroascorbic acid (DHAA) contributing to the risk of each first IA, and γ-aminobutyric acid (GABAs) associated with the first autoantibody against insulin (IAA-first). Methionine and alanine, compounds produced in BCAA metabolism and fatty acids, also preceded IA at different time points. Unsaturated triglycerides and phosphatidylethanolamines decreased in abundance before appearance of either autoantibody. Our findings suggest that IAA-first and GADA-first are heralded by different patterns of DHAA, GABA, multiple amino acids, and fatty acids, which may be important to primary prevention of T1D.
© 2020 by the American Diabetes Association.
Figures




References
-
- Jørgenrud B, Stene LC, Tapia G, et al. . Longitudinal plasma metabolic profiles, infant feeding, and islet autoimmunity in the MIDIA study. Pediatr Diabetes 2017;18:111–119 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- U01 DK063821/DK/NIDDK NIH HHS/United States
- UC4 DK063863/DK/NIDDK NIH HHS/United States
- HHSN267200700014C/DK/NIDDK NIH HHS/United States
- U01 DK063861/DK/NIDDK NIH HHS/United States
- U01 DK063790/DK/NIDDK NIH HHS/United States
- UL1 TR001082/TR/NCATS NIH HHS/United States
- UL1 TR000064/TR/NCATS NIH HHS/United States
- U01 DK063836/DK/NIDDK NIH HHS/United States
- U01 DK063829/DK/NIDDK NIH HHS/United States
- U01 DK063865/DK/NIDDK NIH HHS/United States
- UC4 DK095300/DK/NIDDK NIH HHS/United States
- UC4 DK063861/DK/NIDDK NIH HHS/United States
- UC4 DK063829/DK/NIDDK NIH HHS/United States
- UC4 DK063821/DK/NIDDK NIH HHS/United States
- UC4 DK117483/DK/NIDDK NIH HHS/United States
- UC4 DK063836/DK/NIDDK NIH HHS/United States
- UC4 DK112243/DK/NIDDK NIH HHS/United States
- UC4 DK063865/DK/NIDDK NIH HHS/United States
- U01 DK063863/DK/NIDDK NIH HHS/United States
- UC4 DK106955/DK/NIDDK NIH HHS/United States
- UC4 DK100238/DK/NIDDK NIH HHS/United States